Current evaluation of alemtuzumab in multiple sclerosis

Expert Opinion on Biological Therapy

Volumn 14, Issue 1, 2014, Pages 127-135

  Coyle, Patricia Katherine ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Alemtuzumab; Anti CD52 antibody; Induction therapy; Monoclonal antibody therapy; Multiple sclerosis; Relapsing MS

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DRUG ANTIBODY; FINGOLIMOD; FLUDARABINE; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; OCRELIZUMAB; PARACETAMOL; RITUXIMAB; TERIFLUNOMIDE;

APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BEHCET DISEASE; CLINICAL TRIAL (TOPIC); CYTOLYSIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GUILLAIN BARRE SYNDROME; HEADACHE; HERPES SIMPLEX; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKEMIA; MEDLINE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTOSIS; PREGNANT WOMAN; PRURITUS; PURE RED CELL ANEMIA; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE; URINARY TRACT INFECTION; URTICARIA; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SELECTION; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84890160508     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.866084     Document Type: Article

References (31)

1. O'Gorman C, Lucas R, Taylor B. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 2012;13:11718-52
2. Trojano M, Lucchesse G, Graziano G, et al. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012;7:e48078
3. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009;277(51):542-5
4. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: Why? When? How? CNS Drugs 2013;27:403-9
5. Coles AJ. Alemtuzumab treatment of multiple sclerosis. Semin Neurol 2013;33:66-73
6. Ali R, Nicholas RSJ, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013;73:625-50
7. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis - a focus on alemtuzumab. Clin Immunol 2012;142:25-30
8. Bandala-Sanchez E, Zhang Y, Reinwald S, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol 2013;14:741-8
9. Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogenous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012;7:e39416
10. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:298-304
11. Warner JL, Arnason JE. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol 2012;3:375-89
12. Kousin-Ezewu O, Coles A. Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Ther Adv Chronic Dis 2013;4:97-103
13. Perumal JS, Foo F, Cook P, et al. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. MSJ 2012;18:1197-9
14. Moreau T, Scolding N, Compston A, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301
15. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304
16. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108
17. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-8
18. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
19. Graves J, Galetta SL, Palmer J, et al. Alemtuzumab improves contrast sensitivity in patients with relapsingremitting multiple sclerosis. MSJ 2013;19:1302-9
20. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-48
21. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon- beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-78
22. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
23. Coles AJ, Twyman CI, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
24. Krieger S, Arnold DL, Cohen JA, et al. Alemtuzumab is efficacious in highly active relapsing-remitting multiple sclerosis patients [abstract DX01]. CMSC Annual Meeting DXOI; 2013
25. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012;19:307-11
26. Cossbaum M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77:573-9
27. Aranha AA, Amer S, Reda ES, et al. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review. Endocr Pract 2013;19(5):821-8
28. Costelloe L, Jones J, Coles A, et al. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 2012;12:335-41
29. Coles AJ. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 2013;10:29-33
30. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61
31. Brown JWL, Coles AJ. Alemtuzumab: evidence for its potential in relapsingremitting multiple sclerosis. Drug Des Devel Ther 2013;7:131-8